Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -72.28% | -35.10% | -8.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -72.28% | -35.10% | -8.88% |
| Cost of Revenue | -46.42% | -9.00% | -24.52% | -26.61% | -47.49% |
| Gross Profit | 46.42% | 9.00% | -0.86% | -5.34% | 12.43% |
| SG&A Expenses | -46.09% | -51.22% | -38.75% | -45.14% | -34.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.22% | -37.57% | -33.40% | -37.92% | -40.35% |
| Operating Income | 46.22% | 37.57% | 26.45% | 29.59% | 27.80% |
| Income Before Tax | 42.82% | 31.78% | 20.05% | 17.85% | 13.92% |
| Income Tax Expenses | -210.34% | -172.41% | -86.11% | -90.77% | -38.30% |
| Earnings from Continuing Operations | 42.89% | 31.84% | 20.08% | 17.88% | 13.94% |
| Earnings from Discontinued Operations | 97.78% | 87.37% | 91.86% | 72.72% | -448.03% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.71% | 44.50% | 36.13% | 28.02% | -5.17% |
| EBIT | 46.22% | 37.57% | 26.45% | 29.59% | 27.80% |
| EBITDA | 45.43% | 37.33% | 26.69% | 30.31% | 28.35% |
| EPS Basic | 69.64% | 55.56% | 49.09% | 45.05% | 20.78% |
| Normalized Basic EPS | 65.07% | 48.18% | 39.35% | 46.87% | 41.56% |
| EPS Diluted | 69.64% | 55.56% | 49.10% | 45.06% | 20.74% |
| Normalized Diluted EPS | 65.07% | 48.18% | 39.35% | 46.87% | 41.56% |
| Average Basic Shares Outstanding | 98.03% | 31.12% | 26.68% | 32.06% | 35.03% |
| Average Diluted Shares Outstanding | 98.03% | 31.12% | 26.68% | 32.06% | 35.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
